Cardiovascular risk factors and acute-phase response in idiopathic ascending aortitis: a case control study by Chowdhary, Vaidehi R et al.
Open Access
Available online http://arthritis-research.com/content/11/1/R29
Page 1 of 6
(page number not for citation purposes)
Vol 11 No 1 Research article
Cardiovascular risk factors and acute-phase response in 
idiopathic ascending aortitis: a case control study
Vaidehi R Chowdhary1, Cynthia S Crowson2, Kimberly P Liang3, Clement J Michet Jr1, 
Dylan V Miller4, Kenneth J Warrington1 and Eric L Matteson1
1Division of Rheumatology, Department of Medicine, Mayo Clinic College of Medicine, 200 1st Street SW, Rochester, MN 55905, USA
2Division of Biostatistics, Department of Health Sciences Research, Mayo Clinic College of Medicine, 200 1st Street SW, Rochester, MN 55905, 
USA
3Department of Medicine and Division of Rheumatology, University of Pittsburgh Medical Center, 200 Lothrop Street, Pittsburgh, PA 15213, USA
4Division of Anatomic Pathology, Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, 200 1st Street SW, Rochester, 
MN 55905, USA
Corresponding author: Vaidehi R Chowdhary, chowdhary.vaidehi@mayo.edu
Received: 18 Nov 2008 Revisions requested: 14 Jan 2009 Revisions received: 10 Feb 2009 Accepted: 27 Feb 2009 Published: 27 Feb 2009
Arthritis Research & Therapy 2009, 11:R29 (doi:10.1186/ar2633)
This article is online at: http://arthritis-research.com/content/11/1/R29
© 2009 Chowdhary et al.; licensee BioMed Central Ltd. 
This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Introduction Idiopathic aortitis is a rare condition characterized
by giant cell or lymphoplasmacytic inflammation of the aorta. The
purpose of this study was to describe risk factors for the
development of idiopathic aortitis.
Methods We conducted a case control study of 50 patients
who were age-matched with two control subjects with non-
inflammatory ascending aortic aneurysms. We examined
whether the prevalences of gender, hypertension,
hyperlipidemia, diabetes mellitus, smoking, family history of any
aortic aneurysms, and elevated inflammatory markers differed
between cases and controls.
Results The mean age of cases was 71.6 ± 8.9 years and that
of controls was 71.1 ± 8.9 years. We found female gender
(odds ratio [OR] 2.41, 95% confidence interval [CI] 1.20 to
4.85; P = 0.014) and active smoking (OR 3.37, 95% CI 1.12 to
10.08; P = 0.03) to be associated with idiopathic aortitis. The
association with smoking persisted after adjustment for gender
(OR 3.24, 95% CI 1.05 to 9.96; P = 0.04). There was a trend
toward lower prevalence of diabetes mellitus in cases (OR 0.39,
95% CI 0.11 to 1.43; P = 0.16) but no difference in prevalences
of other risk factors. The median pre-operative erythrocyte
sedimentation rate (ESR) was 20 mm/hour in cases (n = 13)
and 9 mm/hour in controls (n = 22). The median pre-operative
C-reactive protein (CRP) levels were 12 mg/L in cases (n = 8)
and 3 mg/L in controls (n = 6) (normal: <8 mg/L). A higher
proportion of cases versus controls had elevations in ESR (38%
versus 9%; P = 0.075) and CRP (62% versus 0%; P = 0.031).
Conclusions Gender and smoking may interact in complex
mechanisms with immune and proteolytic pathways in older,
less distensible thoracic aortas. Elevated acute-phase reactants
as a marker of systemic inflammation may be present in some
patients.
Introduction
Aneurysms of the thoracic aorta are rare and occur with an
incidence of 5.9 per 100,000 [1]. They are caused by weak-
ening of the aortic wall from hypertension, heritable disorders
like Marfan syndrome, bicuspid valve disease, and inflamma-
tory and infectious processes. Among the systemic inflamma-
tory diseases, thoracic aneurysms and aortitis occur in giant
cell arteritis (GCA), Takayasu arteritis, anti-neutrophil cyto-
plasmic antibody (ANCA)-associated granulomatous vasculi-
tis, spondyloarthropathies, rheumatoid arthritis, and systemic
lupus erythematosus [2]. Rarely, a primary inflammatory proc-
ess characterized by lymphoplasmacytic or giant cell infiltrate
may be responsible. Such patients are termed to have idio-
pathic or isolated aortitis, a condition that is likely different from
GCA or temporal arteritis.
The risk factors for development of aortic complications in
GCA have been well studied [3]. The presence of an aortic
CI: confidence interval; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; GCA: giant cell arteritis; HLA: human leukocyte antigen; MMP: 
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insufficiency murmur, hypertension, coronary artery disease,
hyperlipidemia, and symptoms of polymyalgia rheumatica
(PMR) and elevation of systemic markers of inflammation were
predictors of aneurysm development [4,5]. Persistent
untreated inflammation was postulated as one mechanism for
weakening of aortic wall and consequent aortic complications.
A prospective study of 54 GCA patients who were screened
with a defined protocol found aortic aneurysms in 22% of
patients [6]. Aneurysms were more common in men and
occurred less frequently in patients with hypercholesterolemia.
Treatment of hypercholesterolemia with statins was postu-
lated to be protective for aortic wall enlargement. There was
no difference in the prevalences of smoking, hypertension, and
diabetes in patients with or without aortic abnormalities. Inter-
estingly, at the time of screening, patients with aneurysm/aor-
tic dilatation had lower serum acute-phase reactants and
lower relapse rates and needed shorter periods of prednisone
therapy [6].
Histopathologic examination of the aortic wall revealed a pau-
city of inflammatory infiltrate but multiple foci of disruption of
elastic lamellae, even in areas devoid of inflammation. There
was increased expression of matrix metalloproteinase (MMP)-
2 in the temporal artery as well as aortic tissue, whereas MMP-
9 was found only in temporal artery specimens with active
inflammation [6]. Thus, the process of aneurysm formation in
systemic inflammatory diseases is complex, multifactorial, and
likely involves immune and proteolytic pathways.
The risk factors for development of idiopathic aortitis are not
known. The problem is compounded by the fact that many
patients are diagnosed post-operatively after histopathologic
review of the surgical specimen reveals giant cell inflammation.
Information on pre-operative traditional markers of inflamma-
tion such as erythrocyte sedimentation rate (ESR) and C-reac-
tive protein (CRP) is scanty [7-9]. In this case control study,
we examined whether traditional cardiovascular risk factors
differed in patients with idiopathic aortitis compared with
patients with non-inflammatory aneurysms. We also assessed
the frequency of abnormal pre-operative ESR and CRP in
these patients.
Materials and methods
Subjects
Medical records of all patients at least 18 years old who under-
went surgical resection for ascending aortic aneurysm from 1
January 2000 until 31 July 2006 were searched by means of
a database of pathology specimens. Patients with giant cell or
lymphoplasmacytic aortic inflammation were identified, and
the histopathology slides were reviewed (DVM). Individuals
with aortitis due to identifiable systemic rheumatic diseases,
infectious diseases, and heritable diseases (Marfan syndrome,
bicuspid aortic valve, and Ehlers-Danlos syndrome) were
excluded from the analyses. Individuals who declined to have
their medical records used for research were also excluded.
Patients with idiopathic aortitis constituted our case group.
The cohort of patients serving as controls was drawn from
patients who were undergoing ascending aortic aneurysm
repair during the same period and who fulfilled the exclusion
criteria and did not have giant cell or lymphoplasmacytic
inflammation in the wall of the resected aorta. For each case,
two control subjects matched on age (± 5 years) and year of
surgery were randomly selected from the pool of all controls
with non-inflammatory non-infectious aneurysm.
Data collection
Age, gender, and race were abstracted from the patient med-
ical records. Cardiovascular risk factors assessed included
gender, presence of hypertension, diabetes mellitus (types I
and II), hyperlipidemia, family history of aneurysms, and smok-
ing. Presence of hypertension, hyperlipidemia, or diabetes
mellitus at the time of surgery was identified in the medical
record by ICD-9 (International Statistical Classification of Dis-
eases and Related Health Problems, ninth revision) coding or
by physician diagnosis or the patient provided information on
medical and family history during their visits to the Mayo Clinic
(Rochester, MN, USA). Family history of any aortic aneurysm
was collected from clinical records or patient family history
forms. Smoking history at the time of surgery was classified as
never, current (within last 30 days), or former (quit more than
30 days ago). ESR and CRP values were recorded if they had
been measured within a month pre-operatively.
Statistical analysis
Descriptive statistics were used to summarize the data (mean,
median, proportions, and so on). The association between
case/control status and cardiovascular risk factors was exam-
ined by means of logistic regression models. Each cardiovas-
cular risk factor was examined individually and after
adjustment for gender. Analyses are reported as odds ratio
(OR) with corresponding 95% confidence intervals (CIs). The
Fisher exact test was used to analyze percentage of cases ver-
sus controls with pre-operative elevation in ESR and CRP. In
all cases, two-tailed P values of less than 0.05 were used to
denote statistical significance. For risk factors with a preva-
lence of 25% to 50%, the study had 80% power to detect an
OR of 2.9. For risk factors with a lower prevalence (for exam-
ple, 10%) or a higher prevalence (for example, 70%), this
study had 80% power to detect an OR of 4.0. The study was
approved by the Mayo Clinic Institutional Review Board
(number 08-008786) and was conducted according to its
guidelines.
Results
Subjects
We identified 75 cases of non-infectious aortitis from patients
who had undergone surgical repair during the study period. Of
these, 25 cases were excluded, including patients with a his-
tory of GCA/PMR (n = 15), inflammatory arthritis (n = 2), Taka-
yasu arteritis and Crohn disease (n = 1 each), bicuspid aorticAvailable online http://arthritis-research.com/content/11/1/R29
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valve (n = 3), and Marfan syndrome (n = 1). Two additional
patients, one with a history of thymoma and one mislabeled as
having aortitis without evidence of inflammation in the surgical
specimen, were excluded. The clinical features, imaging find-
ings, and surgical outcomes of 43 of these 50 patients with
idiopathic aortitis have been described previously [10,11]. The
control group consisted of 100 patients matched on age and
year of surgery. The mean age of cases (± standard deviation)
was 71.6 ± 8.9 years and that of controls was 71 ± 8.9 years
(P = 0.69).
Risk factors
The prevalence of cardiovascular risk factors is summarized in
Table 1. Female gender was a risk factor for development of
idiopathic aortitis (OR 2.41, 95% CI 1.20 to 4.85; P = 0.014).
To reduce the probability of selection bias, we then compared
the gender distribution of the 100 controls (69% were male)
with that of the remaining 659 unselected controls (71.5%
were male) from the pool of all patients undergoing surgery for
this indication. There was no difference in gender distribution
between the selected and unselected controls (P = 0.61).
The prevalences of hypertension, hyperlipidemia, and family
history of aortic aneurysms were similar in cases and controls
(Table 1). The prevalence of current smokers was higher in
cases as compared with controls (OR 3.37, 95% CI 1.12 to
10.08; P = 0.02). There was no difference in prevalence of
former or never smokers between the groups. A trend toward
a lower prevalence of diabetes mellitus was seen in cases as
compared with controls (OR 0.39, 95% CI 0.11 to 1.43; P =
0.14).
To evaluate whether gender differences between cases and
controls were masking the differences in cardiovascular risk
factors, we performed gender-adjusted analyses (Table 1).
There was no difference in prevalence of hypertension (OR
1.27, 95% CI 0.57 to 2.81; P = 0.56), hyperlipidemia (OR
0.84, 95% CI 0.42 to 1.69; P = 0.63), or family history of aor-
tic aneurysms (OR 1.37, 95% CI 0.46 to 4.06; P = 0.57). The
prevalence of current smokers continued to be higher even
after adjustment for gender (OR 3.24, 95% CI 1.05 to 9.96; P
= 0.04). There was a trend toward a lower prevalence of dia-
betes mellitus in patients with idiopathic aortitis (OR 0.44,
95% CI 0.12 to 1.64; P = 0.22).
Acute-phase reactants
The pre-operative ESR and CRP measurements in the cases
and controls are presented in Table 2. ESR was determined in
13 cases and 22 controls. The median values were 20 mm/
hour in cases and 9 mm/hour in controls. Among those tested,
a higher proportion of cases had an elevated ESR as com-
pared with controls (38% versus 9%; P = 0.075). The median
level of CRP was higher in cases among patients in whom the
test was performed (n = 8, CRP = 12 mg/L) versus controls
(n = 6, CRP = 3 mg/L; P = 0.010). A significantly higher pro-
portion of cases had an elevated CRP as compared with con-
trols (62% versus none; P = 0.031).
Discussion
To our knowledge, this is the first study to identify risk factors
for development of idiopathic aortitis. Factors independently
associated with an increased risk for idiopathic aortitis discov-
ered at the time of surgical thoracic aneurysm repair in this
study were female gender and active smoking. We did not find
any difference in the prevalence of hypertension, hyperlipi-
demia, or family history of any aortic aneurysm. We found a
trend, though not statistically significant, toward a lower prev-
alence of diabetes mellitus in cases versus controls.
Table 1
Comparison of cardiovascular risk factors in cases with idiopathic aortitis and control patients with non-inflammatory ascending 
thoracic aortic aneurysms
Cases
(n = 50)
Controls
(n = 100)
Odds ratio
(95% CI)
Odds ratio
(95% CI)
adjusted for gender
Gender female, percentage 52 31 2.41 (1.20, 4.85)
Hypertension, percentage 76 69 1.42 (0.66, 3.09) 1.27 (0.57, 2.81)
Hyperlipidemia, percentage 45 51 0.78 (0.39, 1.56) 0.84 (0.42, 1.69)
Diabetes mellitus, percentage 6 14 0.39 (0.11, 1.43) 0.44 (0.12, 1.64)
Smoking, percentage
Current 18 6
Former 52 62 3.37 (1.12, 10.08)a 3.24 (1.05, 9.96)
Never 30 32
Family history of aortic aneurysms, percentage 15 10 1.61 (0.56, 4.63) 1.37 (0.46, 4.06)
aCurrent versus never or former smokers. CI, confidence interval.Arthritis Research & Therapy    Vol 11 No 1    Chowdhary et al.
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The mechanism by which female gender predisposes to
inflammation in the thoracic aorta is not known. The develop-
ment of disease in older post-menopausal females suggests a
role of sex hormones. Human aortic matrix is composed of col-
lagen, which plays a role in load bearing, and elastin, which
conveys elasticity to the aorta. Sex hormones play an impor-
tant role in aortic wall compliance by regulating the elastin/col-
lagen activity [12-14]. 17-β-Estradiol increases the elastin/
collagen ratio, reflecting an increase in distensibility of aorta
and consequently lower systolic blood pressure [15]. In animal
models, oophorectomy increases collagen synthesis and
decreases aortic distensibility [16]. Whether these hormones
interact with immunologic and proteolytic systems to modulate
inflammation in the stiff non-compliant older aorta merits fur-
ther study.
We also found active smoking to be associated with an
increased risk of idiopathic aortitis. The lack of any association
with former or never smoking status indicates an acute but not
cumulative effect. Smoking is an important risk factor for many
rheumatic diseases like lupus and increases the risk of serop-
ositivity in rheumatoid arthritis patients, especially those who
are positive for shared epitope [17,18]. Smoking is the single
most important factor for initiation and rapid growth of abdom-
inal aortic aneurysms, and more patients with inflammatory
abdominal aortic aneurysms tend to be smokers [19-27].
Smoking plays important roles in mediating atherosclerosis,
elastolytic response, and potentiating inflammation [28-30]. It
affects key proteolytic enzymes like MMPs, elastases, cysteine
proteases, and lipoxygenases that are important for extracellu-
lar matrix degradation and aneurysm formation [31,32]. Expo-
sure of endothelial cells to cigarette smoke increases MMP-1,
MMP-8, and MMP-9 levels [33]. High serum levels of MMP-9
are found in moderate-diameter abdominal aortic aneurysms
[34]. The importance of these processes is underscored by
the fact that diabetic patients, in spite of their increased risk for
atherosclerotic vascular disease, are at lower risk of abdominal
aortic aneurysm [35,36]. Incubation of monocytes with gly-
cated type 1 collagen matrices reduced the secretion of MMP-
2, MMP-9, and IL-6 [37]. This may be one mechanism explain-
ing why aneurysmal growth rate is slower in diabetic patients.
Smoking may also interact in complex mechanisms with
immune response genes like human leukocyte antigen (HLA)
to mediate vascular inflammation in predisposed individuals. In
patients with inflammatory abdominal aortic aneurysms, active
smoking and female gender were associated with high-grade
tissue inflammation [21]. HLA-DR B1*01 has been reported to
be protective and HLA-DR B1*02 and HLA-DR B1*04 (DR4,
0401 allele) were significantly associated with increased risk
of tissue inflammation [21,38].
Though tested in only a subset of patients in our study, pre-
operative ESR and CRP were elevated in a higher proportion
of cases than controls. However, these elevations were much
lower when compared with temporal arteritis patients with aor-
titis whose ESR levels range from 82 to 101 mm/hour [4-6]. It
is unclear whether these markers should be determined pre-
operatively in all patients undergoing aortic aneurysm repair or
what the clinical consequence of elevated markers of inflam-
mation should be in terms of potential therapy and follow-up.
The strength of our study is rigorous case definition with avail-
ability of histopathology in cases and controls. The case con-
Table 2
Pre-operative erythrocyte sedimentation rate and C-reactive protein in cases with idiopathic aortitis compared with control patients 
with non-inflammatory aortic aneurysms
Cases Controls P value
Pre-operative ESR
Number tested 13 22
Pre-operative ESR, mm/hour
Mean ± SD 20.5 ± 11.6 11.3 ± 11.1 0.024
Median (range) 20 (2–40) 9 (0–40)
Subjects with elevated ESR 38% 9% 0.075
Pre-operative CRP
Number tested 5 6
Pre-operative CRP, mg/L
Mean ± SD 35 ± 50 3 ± 0.7 0.010
Median (range) 12 (2.5–119) 3 (1.2–3.2)
Subjects with elevated CRP, percentage 60% 0% 0.031
CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; SD, standard deviation.Available online http://arthritis-research.com/content/11/1/R29
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trol design allowed us to study multiple risk factors for this very
rare condition. The identification of risk factors is important for
therapeutic intervention. Smoking cessation may slow down
the inflammatory process and consequent growth of aneurysm
[39]. Advances in molecular pathogenesis will pave the way
for future therapies. Due to their anti-oxidant property, angi-
otensin-converting enzyme inhibitors have been reported to
normalize impaired bradykinin-mediated endothelium-depend-
ent venodilatation in smokers [40], and inhibition of MMP-9 by
doxycycline was useful in preventing aneurysm growth
[41,42].
The potential weaknesses of the study include the inclusion of
surgical cases only. There may be a spectrum of disease, with
mild disease not coming to medical attention. Inclusion of only
cases with surgical specimens as the standard for evaluating
inflammation was chosen to increase the internal validity of the
study. Cases were selected from a large tertiary care referral
center, perhaps introducing a potential bias for more severe
disease. We have not analyzed the risk factors according to
the histopathologic subsets of giant cell or lymphoplasmacytic
inflammation; however, data from our retrospective cohort did
not find any meaningful correlation between clinical features
and histopathology due to small numbers (manuscript in prep-
aration).
Conclusion
Female gender and active smoking are risk factors for devel-
opment of idiopathic aortitis. Future studies are needed to
evaluate the utility of smoking cessation, the role of measure-
ment of inflammatory markers, and medical treatment strate-
gies on disease progress and outcome.
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